What this pack is
ARCOXIA is the brand name in this record; etoricoxib is the generic name. Read both together with the dosage form (oral tablet).
PACK CHECK · MARKET FIRST
ARCOXIAGeneric nameetoricoxib
How this medicine works
A TGA public scheduling record describes etoricoxib as a non-steroidal anti-inflammatory drug (NSAID) and selective cyclo-oxygenase-2 (COX-2) inhibitor. This wording explains a pharmacologic class and pathway only; it does not determine an individual's pain cause, cardiovascular or gastrointestinal risk, suitability, tablet count, course, co-use, stopping or replacement.
Read source: Australia ↗Historical public record · reviewed 2026-08-28More about its action and precautions →Check the market, names, dosage form and route together
A medicine may use different brand names across markets. Keep the market, brand, generic name, dosage form and route together; one matching field does not prove that two packs are the same or interchangeable.
Open the complete product-identity record
Use these fields when the pack, market name or package image needs closer checking. They are evidence boundaries, not substitution instructions.
- International brand name
- ARCOXIA
- Generic name
- etoricoxib
- Dosage-form class
- Etoricoxib 30 mg, 60 mg, 90 mg and 120 mg film-coated oral tablets; blister packaging as listed in TGA ARTG records
- Route
- Oral (product-identity field)
- Package-image status
- No exact original-brand package image is shown This is deliberate: do not use a retailer, repackager or another-market image to identify the pack in hand. See why and what to check instead →
No source-verifiable mainland-China trade-name cue has been established for this record. This does not establish whether the medicine exists, is approved or is available in mainland China. Check pack text and current CDE/NMPA records item by item.
FOR EVERYDAY QUESTIONS
After the leaflet, continue with the question you still need to check
What this page can show
This is a source-traceable public record. It helps you read the product identity and its listed source documents; each market still needs its own current record check.
What to bring to the next conversation
Bring the actual pack, the label or prescription, and a complete medicine list when you speak with a pharmacist or clinician.
NEXT SAFE STEP
Choose the next safe check
A question about changing, combining or splitting?Put the exact packs on one list before a pharmacist or prescriber checks the full context.Open the family medicine list →A question about cost, reimbursement or availability?First lock the market, exact presentation and date. Use local official reimbursement, hospital or pharmacy channels for a current answer rather than a web estimate.Open regulator and market-record entry points →Unsure about a pack or a cross-border product?Photo reading can return possible record matches only. Check the actual product against the current regulator record for its market.Identify pack text locally →Saw a recall, approval or procurement headline?Open the original publisher, then match its product, market and date. Do not make a stop or switch decision from a headline.Read primary-source news →
PRODUCT PRESENTATION IDENTITY
Strength, pack and device identity
Package strength is not an individual dose. These fields help identify the exact labelled product; they do not calculate how much, how often, a missed-use action, splitting, switching or conversion.
4 source-backed strength, pack or device records — open the full list
First match the market, dosage form and labelled amount on the pack in hand. The number of tablets, sachets or devices in a pack is not a personal dose or schedule.
AU · TGA ARTG 131797 (verified 28 Aug 2026)
Etoricoxib 30 mg per tablet; blister pack (Australian TGA ARTG)
Source-text identity card: no displayable exact official package image. The fields below come from the cited label and are not a visual authentication result.
- Product code
- ARTG 131797
- Form and route
- ARCOXIA etoricoxib film-coated oral tablet · oral (product-identity field)
- Container
- blister pack
- Listing review
- Cited public label display reviewed 2026-08-28; actual marketing, stock and availability are not established.
- etoricoxib
- 30 mglabelled amount per tablet; not an individual's tablet count, frequency, course or conversion instruction
AU · TGA ARTG 81456 (verified 28 Aug 2026)
Etoricoxib 60 mg per tablet; blister pack (Australian TGA ARTG)
Source-text identity card: no displayable exact official package image. The fields below come from the cited label and are not a visual authentication result.
- Product code
- ARTG 81456
- Form and route
- ARCOXIA etoricoxib film-coated oral tablet · oral (product-identity field)
- Container
- blister pack
- Listing review
- Cited public label display reviewed 2026-08-28; actual marketing, stock and availability are not established.
- etoricoxib
- 60 mglabelled amount per tablet; not an individual's tablet count, frequency, course or conversion instruction
AU · TGA ARTG 204147 (verified 28 Aug 2026)
Etoricoxib 90 mg per tablet; blister pack (Australian TGA ARTG)
Source-text identity card: no displayable exact official package image. The fields below come from the cited label and are not a visual authentication result.
- Product code
- ARTG 204147
- Form and route
- ARCOXIA etoricoxib film-coated oral tablet · oral (product-identity field)
- Container
- blister pack
- Listing review
- Cited public label display reviewed 2026-08-28; actual marketing, stock and availability are not established.
- etoricoxib
- 90 mglabelled amount per tablet; not an individual's tablet count, frequency, course or conversion instruction
AU · TGA ARTG 81458 (verified 28 Aug 2026)
Etoricoxib 120 mg per tablet; blister pack (Australian TGA ARTG)
Source-text identity card: no displayable exact official package image. The fields below come from the cited label and are not a visual authentication result.
- Product code
- ARTG 81458
- Form and route
- ARCOXIA etoricoxib film-coated oral tablet · oral (product-identity field)
- Container
- blister pack
- Listing review
- Cited public label display reviewed 2026-08-28; actual marketing, stock and availability are not established.
- etoricoxib
- 120 mglabelled amount per tablet; not an individual's tablet count, frequency, course or conversion instruction
PACKAGE-VISUAL STATUS
Four TGA product-level records and official electronic leaflets were reviewed, but no official package image matching one exact strength and pack was retained, so no package visual is shown
This dossier retains ARCOXIA, etoricoxib 30/60/90/120 mg tablets, four ARTG numbers, blister packaging, the current sponsor and PI/CMI routes from TGA ARTG records. No official original-brand image was retained that can be matched one-to-one to a single strength and blister pack; to avoid treating a retail image, version-uncertain image, another-market image or another etoricoxib/NSAID product as the exact ARCOXIA pack, the page withholds package imagery and retains official text identity and electronic leaflets for enlarged reading.
LABEL READING · NOT A PRESCRIPTION
ARCOXIA label reading: 30, 60, 90 and 120 mg identify four exact tablet presentations
Reading level: drug-specific label reading. This record has been expanded around its dosage form or a higher-risk reading question; the current target-market label and professional review still apply.
This module is bounded by four TGA ARTG records and their official PI/CMI routes. It helps check ARCOXIA, etoricoxib, the labelled amount per tablet, oral-tablet form, blister packaging and ARTG number. It provides no individual tablet count, frequency, course, missed-use action, start, stop, co-use, switch or purchase plan.
- Check ARCOXIA, etoricoxib, 30/60/90/120 mg per tablet, oral-tablet form, blister pack, ARTG number and target market together. The four numbers identify different exact tablets; they are not a web formula for an individual's tablet count, assembling another strength from several tablets or self-switching.
- Etoricoxib is in the NSAID/selective COX-2 inhibitor class. Class wording is first a cue to check duplication and risk; it does not permit self-combining, separating, alternating or milligram-converting it with ADVIL, ALEVE, MOBIC, CELEBREX, aspirin, cold/pain products or another etoricoxib product. Have a pharmacist or prescriber review every prescription, OTC product, herb and supplement together with the actual packs.
- The TGA pages for 30, 60 and 120 mg link a Section 14 consent effective until 10 November 2026 concerning former sponsor contact details on packaging. This administrative compliance record is not presented here as product failure, falsification or changed efficacy. If contact details on the actual pack differ from the current record, verify through the current TGA ARTG, PI/CMI or sponsor route.
- With an acute, serious or rapidly worsening concern, use local urgent medical pathways first; do not wait for a web search or self-add, stop, switch or counteract with another pain medicine based on this page.
PHARMACOVIGILANCE · OFFICIAL ROUTES
Check safety information in the right market
Start with the public label or product record linked to this dossier, then use the official safety routes below for the market that applies to the medicine in hand.
Match five details before using a safety record
- Brand and generic nameBoth must match the medicine named by the record.
- Dosage form and strengthTablet, capsule, injection, inhaler, patch and eye drop are not interchangeable.
- Market and notice dateA record applies only to the country or region and date it names.
- Lot, pack and manufacturerRecord these only when the official notice specifically names them.
- Current product informationA historical record may have been superseded by the current label.
This checklist only helps organise the right question. It does not create a personal conclusion about stopping, switching, dose, combination or suitability.
This dossier’s product-level source checkTGA · Australia · Regulatory product record or public product information · 2026-08-28
This dossier’s publicly accessible product-level route has been checked individually. It does not mean that real-time alerts in every country or region have been searched, or that the medicine has or does not have a current risk.
Markets actually represented by the reviewed product documents
- Australia · 5
This is a document-coverage summary, not a claim that the medicine is authorised, supplied, interchangeable or actively monitored in every listed market today.
This record’s label or product-record routeAustralian TGA: ARCOXIA etoricoxib 30 mg tablet blister pack (ARTG 131797) ↗Current regulatory record · reviewed 2026-08-28
Other official market or version documents for this record
These are separately reviewed product documents for the same dossier. Their market, date, dosage form and document status must stay attached to each link; they do not establish interchangeability between products, strengths, packs, indications or countries.
- TGA · Australia · Regulatory product record or public product information · 2026-08-28Australian TGA: ARCOXIA etoricoxib 60 mg tablet blister pack (ARTG 81456) ↗Current regulatory record · reviewed 2026-08-28
- TGA · Australia · Regulatory product record or public product information · 2026-08-28Australian TGA: ARCOXIA etoricoxib 90 mg tablet blister pack (ARTG 204147) ↗Current regulatory record · reviewed 2026-08-28
- TGA · Australia · Regulatory product record or public product information · 2026-08-28Australian TGA: ARCOXIA etoricoxib 120 mg tablet blister pack (ARTG 81458) ↗Current regulatory record · reviewed 2026-08-28
- TGA · Australia · Regulatory product record or public product information · 2026-08-28Australian TGA eBS: official ARCOXIA Product Information (PI) entry route ↗Current regulatory record · reviewed 2026-08-28
This is not a conclusion that the medicine has no risk, warning, recall or newer notice in another market. Start with the checked product-level label above, then use the official market gateways below for the product in hand.
See the reviewed safety-record directory →Global official safety gateways
- NMPA Centre for Drug Reevaluation · Mainland ChinaPrimary NMPA Drug Evaluation Centre gateway for drug-vigilance bulletins, safety notices and adverse-reaction monitoring. Exact products still require checking approval number, dosage form, strength, authorisation holder and notice date item by item.Drug-vigilance bulletins and safety notices ↗reviewed 2026-08-22
- FDA · United StatesPrimary FDA pages for important new safety issues, labelling changes and risk communications.Drug Safety Communications ↗reviewed 2026-08-22
- FDA MedWatch · United StatesU.S. MedWatch safety-information and reporting gateway; a report does not itself establish causality.Safety information and serious-problem reporting ↗reviewed 2026-08-22
- EMA · European Union / European Economic AreaOfficial EU gateway for pharmacovigilance, suspected adverse-reaction reports and PRAC safety assessment.Pharmacovigilance overview and EudraVigilance ↗reviewed 2026-08-22
- MHRA · United KingdomPrimary UK MHRA medicine-safety updates for professionals and the public.Drug Safety Update ↗reviewed 2026-08-22
- PMDA · JapanPMDA’s English official safety gateway; exact products still require checking against the Japanese product page and current documents.Medicine safety information ↗reviewed 2026-08-22
- MFDS · Republic of KoreaMFDS’s primary index for medicine safety letters in the Republic of Korea. The original notices are in Korean and must be read against the named product, dosage form, market and date; they do not automatically apply in another market or decide an individual case.Medicine safety letters ↗reviewed 2026-08-22
- HSA · SingaporeHSA’s public Singapore gateway for suspected adverse-event reporting and medicine-safety information. A report does not itself establish individual causality; exact products still require checking Singapore registration status, dosage form, strength, date and current product information.Adverse-event reporting and medicine-safety information ↗reviewed 2026-08-22
- Health Canada · CanadaHealth Canada’s public MedEffect gateway for medicine and health-product advisories, warnings, recalls, reporting and safety information. Exact products still require checking market, dosage form, strength, notice date and lot item by item.MedEffect Canada: advisories, warnings and recalls ↗reviewed 2026-08-22
- TGA · AustraliaPrimary Australian TGA safety alerts, advisories and monitoring information for therapeutic products.Medicine safety alerts ↗reviewed 2026-08-22
- Swissmedic · SwitzerlandOfficial Swissmedic gateway for pharmacovigilance, signal assessment and suspected adverse-reaction reporting; a report or signal does not itself confirm individual causality.Pharmacovigilance and suspected adverse-reaction reporting ↗reviewed 2026-08-22
- Medsafe · New ZealandNew Zealand Medsafe gateway for public and professional medicine safety communications and archives; older notices may have been superseded by current product information.Medicine safety communications ↗reviewed 2026-08-22
- SAHPRA · South AfricaSAHPRA’s safety-information, alerts and pharmacovigilance gateway for the public and professionals in South Africa. An official alert does not itself mean a product is unsafe in every circumstance; exact products still require checking South African registration status, dosage form, strength, notice date and current product information.Medicine safety information, alerts and pharmacovigilance ↗reviewed 2026-08-22
- WHO · GlobalWHO’s cross-market safety-alert archive; every historical notice must be read against its date, named product and market.Medicine and vaccine safety-alert archive ↗reviewed 2026-08-22
- Anvisa · BrazilAnvisa’s primary Brazilian pharmacovigilance gateway for alerts, bulletins, risk communication and VigiMed reporting. Exact products still require checking Brazilian authorisation status, dosage form, strength and notice date item by item.Pharmacovigilance, alerts and VigiMed ↗reviewed 2026-08-22
This card brings together the medicine-specific product route and 15 market-level official vigilance gateways. It does not mean real-time alerts for this medicine have been searched in every country or region, or that the medicine has a new alert, recall or risk conclusion. Match brand, generic name, dosage form, strength, market and notice date item by item; do not self-stop, switch, increase or reduce use from a headline.
For severe or rapidly worsening symptoms, suspected overdose, a severe allergic reaction, loss of consciousness or another emergency, use local emergency services. Do not wait for an online alert search or change a medicine from this page.
PRIVATE FAMILY LIST
Bring this record into a local medicine list
Only the brand, generic name, dosage form and route are added, and they stay in this browser. Copy strength, label directions, start/stop history and any concern from the actual pack; this tool does not calculate a dose or decide combination, switching or stopping.
Add to the family medicine list →PACK · LABEL · MEDICINE LIST
Six checks for this medicine pack
Use this card to organise questions about ARCOXIA (etoricoxib). Keep the exact pack, its current label and the full medicine list together.
Identify the exact product
ARCOXIA is the brand in this record and etoricoxib is the active-ingredient name. Check both with the dosage form (Etoricoxib 30 mg, 60 mg, 90 mg and 120 mg film-coated oral tablets; blister packaging as listed in TGA ARTG records) and the market on the actual pack.
Read the labelled strength in context
mg, mcg, mg/mL or a percentage describes the labelled amount in one tablet, capsule, measured volume, spray or other unit. It is not an answer to how many units a person should take.
Check before splitting or opening
Before splitting, crushing, chewing or opening anything, find an explicit instruction for this exact product in its current label and ask a pharmacist. A score line or a previous pack is not enough by itself.
Put every product on one list
Include prescriptions, over-the-counter products, eye drops, creams, vitamins, minerals, herbs and supplements. A pharmacist or prescriber needs the whole list before any combination, alternation, switch or stop is considered.
Ask a specific pharmacogenetics question
Ask which medicine, which gene and what clinical decision a result could change. A gene–drug association does not mean broad genetic testing is needed for everyone and must not be used to change treatment without professional review.
Know when to seek urgent help
For a suspected overdose, a severe allergic reaction, fainting or difficulty breathing, use the local emergency or poison-information service now. Do not wait for a website reply or alter several medicines to test what caused it.
This card does not calculate a dose, decide whether medicines can be combined, or replace a clinician or pharmacist. Market-specific current labels and the person's full context still need review.
MARKET DOCUMENTS · READ SEPARATELY
Enlarged market leaflets and regulator documents
Each link retains its own market, date, dosage form and document status. These documents support larger-print reading and item-by-item checking; they do not make products, strengths, packs, indications or use between countries or regions interchangeable.
- Australian TGA: ARCOXIA etoricoxib 30 mg tablet blister pack (ARTG 131797) ↗Current regulatory record · reviewed 2026-08-28
- Australian TGA: ARCOXIA etoricoxib 60 mg tablet blister pack (ARTG 81456) ↗Current regulatory record · reviewed 2026-08-28
- Australian TGA: ARCOXIA etoricoxib 90 mg tablet blister pack (ARTG 204147) ↗Current regulatory record · reviewed 2026-08-28
- Australian TGA: ARCOXIA etoricoxib 120 mg tablet blister pack (ARTG 81458) ↗Current regulatory record · reviewed 2026-08-28
- Australian TGA eBS: official ARCOXIA Product Information (PI) entry route ↗Current regulatory record · reviewed 2026-08-28
HOW IT WORKS · NOT A TREATMENT PLAN
How etoricoxib works: selective COX-2 inhibition is a mechanism cue, not a personal selection rule
- “Selective COX-2” is not synonymous with “safer for everyone” or permission to combine with another NSAID. Professional review still requires the actual product, current leaflet, prior reactions, cardiovascular/gastrointestinal/kidney context and complete medicine list.
- A shared class, purpose or nearby milligram number does not establish that ARCOXIA is equivalent to, self-substitutable for or combinable with CELEBREX, MOBIC, ADVIL, ALEVE or another etoricoxib product. Dosage form, strength, market, label version and other ingredients all require item-by-item review.
- A mechanism explanation does not replace pharmacovigilance, interaction review or symptom assessment. When a prescription, OTC pain/cold medicine, anticoagulant, herb or supplement is added, or a new serious concern occurs, take the exact pack and full medicine list to a pharmacist or care team; use local urgent-care channels first for an acute serious concern.
SOURCE EVIDENCE REGISTER
Source evidence map
Every public link is labelled with its market, document status and document type. A historical public record is not a current label, and an official lookup entry is not a product-specific record.
- Australian TGA: ARCOXIA etoricoxib 30 mg tablet blister pack (ARTG 131797) ↗Current regulatory record · reviewed 2026-08-28
- Australian TGA: ARCOXIA etoricoxib 60 mg tablet blister pack (ARTG 81456) ↗Current regulatory record · reviewed 2026-08-28
- Australian TGA: ARCOXIA etoricoxib 90 mg tablet blister pack (ARTG 204147) ↗Current regulatory record · reviewed 2026-08-28
- Australian TGA: ARCOXIA etoricoxib 120 mg tablet blister pack (ARTG 81458) ↗Current regulatory record · reviewed 2026-08-28
- Australian TGA eBS: official ARCOXIA Product Information (PI) entry route ↗Current regulatory record · reviewed 2026-08-28
- Australian TGA eBS: official ARCOXIA Consumer Medicine Information (CMI) entry route ↗Current regulatory record · reviewed 2026-08-28
- Australian TGA: ARCOXIA 30 mg Section 14 consent (former sponsor contact details; effective to 10 Nov 2026) ↗Current regulatory record · reviewed 2026-08-28
- Australian TGA: public scheduling record for etoricoxib as a prescription medicine (2003; historical regulatory document) ↗Historical public record · reviewed 2026-08-28
SOURCE-TRACEABLE ARCHIVE
ARCOXIAetoricoxib
This page links to public primary-source material for ARCOXIA. The archive is historical or documentary evidence only; it does not by itself establish originator status, product quality, current labelling, availability or sale eligibility.
DOCUMENT TIMELINE
Document timeline
TGA ARTG dates for ARCOXIA 60 mg and 120 mg
TGA lists 11 Oct 2002 as the ARTG date for ARTG 81456 (60 mg) and ARTG 81458 (120 mg). The date anchors two Australian regulatory product records only; it does not establish another strength, market, supply, individual tablet count or course.
Australian TGA: ARCOXIA etoricoxib 60 mg tablet blister pack (ARTG 81456) ↗TGA ARTG date for ARCOXIA 30 mg
TGA lists ARCOXIA etoricoxib 30mg tablet blister pack as the product name for ARTG 131797 and 11 Apr 2008 as its ARTG date. The 30 mg figure is the labelled amount per exact tablet, not an individual strength selection or tablet-count conversion.
Australian TGA: ARCOXIA etoricoxib 30 mg tablet blister pack (ARTG 131797) ↗TGA ARTG date for ARCOXIA 90 mg
TGA lists ARCOXIA etoricoxib 90mg tablet blister pack as the product name for ARTG 204147 and 5 Nov 2013 as its ARTG date. The node locates this Australian product record only and does not mean 90 mg is suitable for any individual.
Australian TGA: ARCOXIA etoricoxib 90 mg tablet blister pack (ARTG 204147) ↗Section 14 packaging-contact compliance record commenced
TGA CON-1408 states that some ARCOXIA packaging carries former sponsor contact details and that the consent is effective until 10 Nov 2026. This page treats it only as an administrative compliance boundary for packaging contact details and does not infer efficacy, composition, authenticity, product failure or changed quality.
Australian TGA: ARCOXIA 30 mg Section 14 consent (CON-1408) ↗
MARKET SCOPE
Market-record boundary
Australia
Four current TGA ARTG product records and official PI/CMI routes linkedThe dossier separately records 30, 60, 90 and 120 mg labelled per tablet, four ARTG numbers, tablet form and blister-pack text identities. It does not authenticate a product or establish stock, actual supply, purchase, individual tablet count, frequency, course, co-use, stopping, switching or interchangeability.
Mainland China, the United States, the EU, Japan and other markets
Current market record not establishedNo local trade name, approval, packaging, supply, sale eligibility, originator/generic relationship or interchangeability is inferred from the Australian ARTG name, date, sponsor, PI/CMI, COX-2 class or blister packaging; every market requires exact-product review against current local regulatory material.
How to read this record
Read each document in its stated market, date and dosage-form context. A historical record is not a current label and does not support individual medical, substitution or purchasing conclusions.
RECORD FAQ
Record questions
Can 30, 60, 90 and 120 mg be converted into tablet counts or substituted for one another?
No. They are labelled amounts per tablet for four exact presentations. The website does not generate an individual's strength, tablet count, frequency, course, missed-use make-up or switching rule; use the actual prescription, exact pack, current target-market leaflet and pharmacist/prescriber review.
If sponsor contact details on the pack differ from this page, does that mean the medicine is falsified or defective?
That conclusion cannot be made. The current TGA Section 14 record concerns former sponsor contact details on some packaging and has a defined period; it is an administrative compliance record, not a finding on authenticity, composition, efficacy or quality. Verify the exact ARTG number, current PI/CMI and current TGA or sponsor route; use local regulatory or medical channels for a serious concern.
READ NEXT
Related reading
Evidence status
The listed links are public sources selected for traceability. They must be rechecked against the current target-market record before any use beyond reading and research.